pipette
ESEspañol

Near point of care C-Reactive Protein and Serum Amyloid-A Test met WHO target product profile for TB screening

T. P. Setiabudiawan, N. Iswandari, M. Korompis, R. C. Koesoemadinata, E. Susandi, I. D. Kulsum, D. K. Turbawaty, B. Alisjahbana

PreprintBold claims, read criticallyReal-world use

In the authors' words

Background: TB eradication strategies in high burden countries need affordable, scalable, and accessible screening tools. This study investigated the diagnostic accuracy of C-reactive protein (CRP), serum amyloid A (SAA), and interferon gamma-induced protein 10 (IP-10) as potential screening tools. Methods. This cross-sectional diagnostic study investigated stored archived serum samples from three groups of subjects; bacteriology confirmed symptomatic TB group (n=57), probable TB (n=56) and healthy controls (n=60). CRP and SAA concentrations were measured using near point-of-care fluorescence immunoassay (NPOCT-FIA), while IP-10 was measured using enzyme-linked immunosorbent assay (ELISA). Diagnostic performance of individual and combined biomarkers was evaluated Results Receiver operating characteristic analysis demonstrated excellent diagnostic performance of serum amyloid A (SAA) and C-reactive protein (CRP) for identifying confirmed tuberculosis (TB). Compared with probable TB and healthy controls, SAA achieved an AUC of 0.961 (cut-off >31.0 mg/L), with 96.5% sensitivity and 88.6% specificity, while CRP achieved an AUC of 0.953 (cut-off 21.3 mg/L), with 96.5% sensitivity and 86.0% specificity. Interferon gamma-induced protein 10 (IP-10) showed poor discrimination (AUC 0.545). Combined CRP and SAA achieved 100.0% sensitivity and 83.3% specificity. Conclusion: SAA and CRP met WHO target product profile criteria for TB triage screening.

Main resultThe abstract does not state a limitation.

Appeared: Thursday, November 12. medRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.10.26367691